MCID: PLY011
MIFTS: 63

Polycystic Ovary Syndrome

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Polycystic Ovary Syndrome

MalaCards integrated aliases for Polycystic Ovary Syndrome:

Name: Polycystic Ovary Syndrome 38 12 52 41 42 14 69
Polycystic Ovaries 12 29 52
Polycystic Ovarian Syndrome 72 50
Pcos 12 50
Polycystic Ovarian Disease 12
Stein-Leventhal Syndrome 12
Stein-Leventhal Synd. 12
Multicystic Ovaries 12
Polycystic Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11612
ICD10 33 E28.2
ICD9CM 35 256.4
MeSH 42 D011085
NCIt 47 C26862
UMLS 69 C0032460

Summaries for Polycystic Ovary Syndrome

MedlinePlus : 41 polycystic ovary syndrome (pcos) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. pcos causes cysts (fluid-filled sacs) to grow on the ovaries. symptoms include irregular menstrual periods infertility pelvic pain excess hair growth on the face, chest, stomach, or thighs weight gain acne or oily skin patches of thickened skin women with pcos are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure. pcos is more common in women who are obese, or have a mother or sister with pcos. to diagnose pcos, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound. there is no cure, but diet, exercise, and medicines can help control the symptoms. birth control pills help women have normal periods, reduce male hormone levels, and clear acne. treatments for infertility caused by pcos may include medicines, surgery, and in vitro fertilization (ivf). nih: national institute of child health and human development

MalaCards based summary : Polycystic Ovary Syndrome, also known as polycystic ovaries, is related to ovarian hyperstimulation syndrome and thrombophilia, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are p70S6K Signaling and mTOR signaling pathway (KEGG). The drugs Metformin and Cyproterone Acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and endocrine/exocrine gland

NIH Rare Diseases : 50 polycystic ovarian syndrome (pcos) is a health problem that can affect a woman's menstrual cycle, ability to have children, hormones, heart, blood vessels, and appearance. women with this condition typically have high levels of  hormones called androgens, missed or irregular periods, and many small cysts in their ovaries. the cause of pcos is unknown, but probably involves a combination of genetic and environmental factors. treatment for pcos may involve birth control pills and medications for diabetes and infertility. medicines called anti-androgens are also used to speed the growth of hair and clear acne. last updated: 6/7/2016

Disease Ontology : 12 A syndrome characterized by hyperandrogenism, polycystic ovaries, hirsutism, oligomenorrhea or amenorrhea, anovulation and excessive body weight.

Wikipedia : 72 Polycystic ovary syndrome (PCOS) is a set of symptoms due to elevated androgens (male hormones) in... more...

Related Diseases for Polycystic Ovary Syndrome

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 210, show less)
id Related Disease Score Top Affiliating Genes
1 ovarian hyperstimulation syndrome 30.3 CYP19A1 FSHR GNRH1
2 thrombophilia 29.6 GNRH1 IGF1 IGFBP1 INS PRL
3 polycystic ovary syndrome 1 12.1
4 hyperandrogenism 11.4
5 aromatase deficiency 11.3
6 cortisone reductase deficiency 11.2
7 intellectual deficit buenos-aires type 10.9 INS INSR
8 ovarian disease 10.9
9 acth-independent macronodular adrenal hyperplasia 10.9
10 hair-an syndrome 10.9
11 ovarian cyst 10.9
12 cortisone reductase deficiency 1 10.9
13 multicystic dysplastic kidney 10.9 H6PD HSD11B1
14 obesity 10.9
15 oxyphilic adenoma 10.8 IGF1 IRS1
16 hypomagnesemia 3, renal 10.8 HSD11B1 INS LEP
17 selenium poisoning 10.8 IGF1 INS
18 polyneuropathy 10.8 CYP19A1 SHBG
19 ulcerative blepharitis 10.8 IGF1 INS PRL
20 protein s deficiency 10.7 IGF1 INS PRL
21 hyperlipoproteinemia, type ib 10.7 IGF1 INS INSR
22 glioblastoma proneural subtype 10.7 CYP19A1 PRL SHBG
23 mitochondrial complex iii deficiency, nuclear type 9 10.7 CYP19A1 FST
24 chondroma 10.7 IGF1 INS LEP
25 fibrolamellar carcinoma 10.7 IGF1 INS PRL
26 capillary disease 10.7 CYP19A1 PRL SHBG
27 vertebral artery occlusion 10.7 GNRH1 INS PRL
28 osteopathia striata with cranial sclerosis 10.7 CYP19A1 SHBG
29 lactic acidosis 10.7 GNRH1 INS PRL
30 male reproductive organ benign neoplasm 10.7 IGF1 INS PRL
31 african histoplasmosis 10.7 GNRH1 PRL
32 maturity-onset diabetes of the young, type 10 10.6 IGFBP1 INS SHBG
33 internal hemorrhoid 10.6 GNRH1 PRL SHBG
34 diabetic encephalopathy 10.6 IGF1 INS LEP
35 mucinoses 10.6 INS INSR LEP SHBG
36 periampullary adenoma 10.6 IGF1 INS LEP
37 lipodystrophy, familial partial, type 2 10.6 INS LEP
38 uterine corpus adenocarcinofibroma 10.6 GNRH1 PRL SHBG
39 diencephalic neoplasm 10.6 GNRH1 INS PRL
40 complement component 8 deficiency 10.6 GNRH1 IGF1 LEP
41 skin meningioma 10.6 INS LEP PRL SHBG
42 plague 10.6 IGF1 PRL SHBG
43 aromatase excess syndrome 10.6 CYP19A1 GNRH1 INS
44 fetal parvovirus syndrome 10.6 IGF1 INS INSR LEP
45 prostate leiomyoma 10.6 GNRH1 PRL
46 retroperitoneal sarcoma 10.6 GNRH1 PRL SHBG
47 neurogenic arthropathy 10.5 IGF1 INS IRS1 LEP
48 glomerulosclerosis, focal segmental, 1 10.5 IGF1 INS INSR IRS1
49 hypertrichosis 10.5 IGF1 INS IRS1 LEP
50 alpha-methylacyl-coa racemase deficiency 10.5 GNRH1 IGF1 PRL
51 dientamoebiasis 10.5 INS INSR IRS1 LEP
52 endometriosis 10.5 PRL SHBG
53 adenomatoid tumor 10.5 GNRH1 PRL
54 nephrogenic adenofibroma 10.5 CYP19A1 GNRH1 LEP
55 chromosome 11p13 deletion syndrome, distal 10.5 IGF1 LEP PRL
56 infertility 10.5
57 uterine ligament clear cell adenocarcinoma 10.5 GNRH1 IGF1 INS PRL
58 adamantinous craniopharyngioma 10.5 GNRH1 IGF1 INS PRL
59 allergic asthma 10.4 GNRH1 IGF1 INS PRL
60 bile duct signet ring cell carcinoma 10.4 IGF1 IGFBP1 SHBG
61 intraventricular meningioma 10.4 CYP17A1 CYP19A1 HSD3B2
62 intermittent squint 10.4 GNRH1 PRL
63 cleft lip and palate malrotation cardiopathy 10.4 CYP21A2 LEP
64 acute thyroiditis 10.4 CYP19A1 FSHR SHBG
65 endotheliitis 10.4
66 anovulation 10.4
67 medullomyoblastoma 10.4 CYP17A1 GNRH1 IGF1 SHBG
68 precocious puberty, male 10.4 CYP19A1 FSHR
69 haverhill fever 10.4 CYP19A1 GNRH1 IGF1 PRL
70 lymphoepithelioma-like carcinoma 10.3 GNRH1 PRL
71 peroneal neuropathy 10.3 IGF1 INS INSR IRS1 LEP
72 alpha thalassemia-x-linked intellectual disability syndrome 10.3 CYP21A2 H6PD HSD11B1
73 glucose intolerance 10.3
74 epilepsy, idiopathic generalized 11 10.3 CYP19A1 CYP21A2 SHBG
75 chylomicron retention disease 10.3 CYP19A1 HSD11B1 IGF1 LEP SHBG
76 46,xx gonadal dysgenesis epibulbar dermoid 10.3 CYP21A2 HSD3B2
77 adrenal cortex disease 10.2 CYP21A2 LEP PRL
78 insulin-like growth factor i 10.2
79 hyperinsulinism 10.2
80 thyroiditis 10.2
81 gastrojejunal ulcer 10.2 CYP17A1 CYP19A1 CYP21A2
82 myh-9 related disease 10.2 INS LEP
83 inherited metabolic disorder 10.2 HSD11B1 IGF1 INS IRS1 LEP SHBG
84 survival motor neuron spinal muscular atrophy 10.2 IGF1 INS IRS1 LEP PRL SHBG
85 acanthosis nigricans 10.2
86 weill-marchesani syndrome 10.2 CYP17A1 CYP19A1 CYP21A2
87 gestational diabetes 10.2
88 amenorrhea 10.2
89 dfna2 nonsyndromic hearing loss 10.1 CYP17A1 CYP21A2
90 presenile dementia, kraepelin type 10.1 CYP19A1 CYP21A2 GNRH1
91 fatty liver disease 10.1
92 liver disease 10.1
93 hyperprolactinemia 10.1
94 atherosclerosis 10.1
95 monosomy 13q34 10.1 CYP11A1 CYP21A2
96 exostosis 10.0 IGF1 IGFBP1 INS INSR LEP SHBG
97 autonomic dysfunction 10.0
98 precocious puberty 10.0
99 hepatitis 10.0
100 benign peritoneal mesothelioma 10.0 CYP21A2 GNRH1 HSD3B2
101 acne 10.0
102 capillary lymphangioma 10.0 FSHR GNRH1 IGF1 INS SHBG
103 antidepressant type abuse 10.0 CAPN10 INS INSR IRS1 LEP SHBG
104 pulmonary blastoma 10.0 CYP11A1 CYP17A1 CYP21A2
105 aortic valve prolapse 10.0 CYP19A1 FSHR GNRH1 PRL
106 acute gonococcal salpingitis 10.0 FSHR GNRH1 LEP PRL SHBG
107 mental retardation, autosomal recessive 50 10.0 CYP11A1 CYP17A1 CYP21A2
108 gallbladder adenoma 9.9 CYP11A1 CYP17A1 CYP21A2
109 kunjin encephalitis 9.9 CYP11A1 CYP17A1 CYP21A2
110 central precocious puberty 9.9
111 personality disorder 9.9
112 intracranial hypertension 9.9
113 sleep apnea 9.9
114 hyperglycemia 9.9
115 nonalcoholic steatohepatitis 9.9
116 hypothyroidism 9.9
117 borderline personality disorder 9.9
118 prostatitis 9.9
119 ocular hypotension 9.9 CYP19A1 CYP21A2
120 adrenal cortical adenocarcinoma 9.9 CYP11A1 CYP17A1 CYP21A2
121 acute myocarditis 9.9 CYP21A2 GNRH1 HSD11B1 INS PRL
122 hypermobility syndrome 9.9 CYP11A1 CYP17A1 CYP21A2
123 androgenic alopecia 9.8
124 endometrial cancer 9.8
125 congenital adrenal hyperplasia 9.8
126 heart disease 9.8
127 artery disease 9.8
128 vascular disease 9.8
129 idiopathic central precocious puberty 9.8
130 breast disease 9.8
131 obstructive sleep apnea 9.8
132 goiter 9.8
133 hepatocellular adenoma 9.8
134 graves' disease 9.8
135 nodular goiter 9.8
136 pancreatitis 9.8
137 hemochromatosis 9.8
138 cervicitis 9.8
139 alopecia 9.8
140 adenoma 9.8
141 coronary artery disease 9.8
142 lipodystrophy 9.8
143 gingivitis 9.8
144 posterior uveal melanoma 9.8 CYP11A1 CYP17A1 CYP21A2 HSD11B1
145 lethal congenital contracture syndrome 10 9.8 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
146 short bowel syndrome 9.8 IGF1 IGFBP1 INS INSR IRS1 LEP
147 liver sarcoma 9.8 CYP11A1 CYP17A1 CYP19A1 CYP21A2
148 hepatic adenoma, somatic 9.8 IGF1 IGFBP1 INS INSR IRS1 LEP
149 basal cell carcinoma 7 9.8 CYP11A1 CYP17A1 CYP19A1 CYP21A2
150 cherubism 9.7
151 familial partial lipodystrophy 9.7
152 hereditary angioedema 9.7
153 psoriasis 9.7
154 chlamydia 9.7
155 lipid metabolism disorder 9.7
156 hyperhomocysteinemia 9.7
157 angioedema 9.7
158 teratoma 9.7
159 headache 9.7
160 mood disorder 9.7
161 hypoglycemia 9.7
162 peutz-jeghers syndrome 9.7
163 anxiety disorder 9.7
164 retinitis 9.7
165 3-beta-hydroxysteroid dehydrogenase deficiency 9.7
166 refractory anemia 9.7
167 vogt-koyanagi-harada disease 9.7
168 vaginitis 9.7
169 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 9.7
170 ectopic pregnancy 9.7
171 thrombocytosis 9.7
172 androgen insensitivity 9.7
173 thrombosis 9.7
174 acromegaly 9.7
175 homocysteinemia 9.7
176 mucositis 9.7
177 eclampsia 9.7
178 mosaic variegated aneuploidy syndrome 9.7
179 non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 9.7
180 acute insulin response 9.7
181 endometrial disease 9.7
182 generalized anxiety disorder 9.7
183 cystadenoma 9.7
184 conjunctivitis 9.7
185 pre-eclampsia 9.7
186 estrogen excess 9.7
187 myoma 9.7
188 endometrial adenocarcinoma 9.7
189 tetraploidy 9.7
190 transsexualism 9.7
191 papilledema 9.7
192 adenocarcinoma 9.7
193 trisomy 12 mosaicism 9.7
194 myelodysplastic syndrome 9.7
195 morbid obesity 9.7
196 eating disorder 9.7
197 cardiovascular disease risk factor ) 9.7
198 clear cell acanthoma 9.7 CYP11A1 CYP17A1 CYP21A2 HSD3B2
199 first-degree atrioventricular block 9.6 CYP11A1 CYP17A1 CYP21A2 HSD3B2
200 lung cancer susceptibility 2 9.6 IGF1 IGFBP1 INS INSR IRS1 LEP
201 avoidant personality disorder 9.6 CYP19A1 FSHR GDF9 GNRH1 INS PRL
202 sphingolipidosis 9.4 CYP17A1 CYP19A1 CYP21A2 GNRH1 INS PRL
203 porokeratosis 9.3 CYP19A1 FSHR GNRH1 IGF1 INS LEP
204 spondylolysis 9.3 CYP17A1 CYP19A1 FSHR GDF9 GNRH1 INS
205 adrenoleukodystrophy 9.3 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 PRL
206 maturity-onset diabetes of the young 6 9.2 CAPN10 HSD11B1 IGF1 IGFBP1 INS INSR
207 von hippel-lindau syndrome 9.2 CAPN10 HSD11B1 IGF1 IGFBP1 INS INSR
208 pseudopterygium 9.0 CYP19A1 FSHR GDF9 GNRH1 IGF1 IGFBP1
209 pelvic muscle wasting 8.2 CYP17A1 CYP19A1 CYP21A2 GNRH1 HSD3B2 IGF1
210 precursor b lymphoblastic lymphoma/leukemia 5.6 CAPN10 CYP11A1 CYP17A1 CYP19A1 CYP21A2 FSHR

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome:



Diseases related to Polycystic Ovary Syndrome

Symptoms & Phenotypes for Polycystic Ovary Syndrome

UMLS symptoms related to Polycystic Ovary Syndrome:


pelvic pain

GenomeRNAi Phenotypes related to Polycystic Ovary Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.78 LEP IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.78 LEP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.78 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.78 CYP21A2 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.78 INSR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.78 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.78 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.78 IGF1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.78 INSR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.78 CYP21A2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.78 SHBG
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.78 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.78 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.78 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.78 CYP21A2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.78 INSR LEP SHBG CYP21A2 IGF1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.78 LEP
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.78 IGF1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.78 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.78 LEP
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.78 INSR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.78 INSR
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.78 IGF1

MGI Mouse Phenotypes related to Polycystic Ovary Syndrome:

44 (showing 15, show less)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.39 CAPN10 CYP11A1 CYP19A1 FSHR FST GDF9
2 homeostasis/metabolism MP:0005376 10.36 INS INSR IRS1 LEP PRL CAPN10
3 growth/size/body region MP:0005378 10.31 INSR IRS1 LEP CAPN10 CYP11A1 CYP19A1
4 cellular MP:0005384 10.3 CYP17A1 CYP11A1 CYP19A1 FSHR FST HSD11B1
5 cardiovascular system MP:0005385 10.28 CAPN10 CYP11A1 CYP19A1 FSHR FST HSD11B1
6 immune system MP:0005387 10.25 CAPN10 CYP11A1 CYP19A1 FSHR GNRH1 HSD11B1
7 hematopoietic system MP:0005397 10.22 CYP19A1 FSHR GNRH1 HSD11B1 IGF1 INS
8 adipose tissue MP:0005375 10.2 CAPN10 CYP19A1 FSHR HSD11B1 IGF1 INS
9 liver/biliary system MP:0005370 10.11 CYP19A1 GNRH1 HSD11B1 IGFBP1 INS INSR
10 integument MP:0010771 10.06 CYP19A1 FSHR FST GNRH1 HSD11B1 IGF1
11 muscle MP:0005369 10.02 CYP11A1 CYP19A1 FST H6PD HSD11B1 IGF1
12 nervous system MP:0003631 10 CYP11A1 CYP19A1 FSHR FST GNRH1 HSD11B1
13 reproductive system MP:0005389 9.73 GDF9 GNRH1 IGF1 INS CYP11A1 INSR
14 renal/urinary system MP:0005367 9.7 CAPN10 CYP19A1 GNRH1 IGF1 INS INSR
15 skeleton MP:0005390 9.28 CYP17A1 CYP19A1 FSHR FST GNRH1 IGF1

Drugs & Therapeutics for Polycystic Ovary Syndrome

Drugs for Polycystic Ovary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 325, show less)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
2
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Ganirelix Approved Phase 4,Early Phase 1 123246-29-7, 124904-93-4 25081094
7
Drospirenone Approved Phase 4,Phase 3,Phase 1 67392-87-4 68873
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
9
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
11
Zinc Approved Phase 4,Early Phase 1 7440-66-6 32051 23994
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
13
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
15
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 1 71-58-9
16
Moxonidine Approved Phase 4 75438-57-2 4810
17
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
22 Racepinephrine Approved Phase 4
23
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 3911 657181
24
Menotropins Approved Phase 4,Phase 1,Phase 2 61489-71-2, 9002-68-0 5360545
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
26
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
27
Alogliptin Approved Phase 4 850649-61-5 11450633
28
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
29
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
30
Tamoxifen Approved Phase 4 10540-29-1 2733526
31
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
32
Desogestrel Approved Phase 4,Phase 3 54024-22-5 40973
33
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
37
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 10883523 5280795
38
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
40
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
43
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
44
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
45
Enclomiphene Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15690-57-0
46
Resveratrol Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
47
2,4-thiazolidinedione Investigational Phase 4,Early Phase 1 2295-31-0
48 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Androgen Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Androgens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
51 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
52 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
53
Cyproterone Phase 4,Phase 2,Phase 3,Early Phase 1 2098-66-0 5284537
54 Cyproterone acetate, ethinyl estradiol drug combination Phase 4,Phase 2
55 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
56 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
57 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 979-32-8
58 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
59 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
60 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
61 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
62 Antidepressive Agents Phase 4
63 Anti-Obesity Agents Phase 4,Phase 3,Phase 2
64 Appetite Depressants Phase 4,Phase 3
65 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
66 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
67 Psychotropic Drugs Phase 4
68 Clomiphene Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
69 Zuclomiphene Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
70 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
71 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
72 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
73 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
74 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
75 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
76 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
77 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
78 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
79 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
80 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
81 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
82 Contraceptives, Oral Phase 4,Phase 2,Phase 3
83 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
84 Deslorelin Phase 4,Phase 3
85 Luteolytic Agents Phase 4,Phase 3
86 Triptorelin Pamoate Phase 4,Phase 3
87 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
88 Contraceptives, Oral, Combined Phase 4,Phase 2,Phase 3
89 diuretics Phase 4,Phase 2,Phase 1,Early Phase 1
90 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 1,Early Phase 1
91 Drospirenone and ethinyl estradiol combination Phase 4,Phase 3,Phase 1
92 Hemostatics Phase 4,Phase 2
93 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
94 Mineralocorticoids Phase 4,Phase 2,Phase 1,Early Phase 1
95 Natriuretic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
96 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
97 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
98 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
99 Liver Extracts Phase 4,Phase 2
100 Antimetabolites Phase 4,Phase 3,Phase 2
101 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
102 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
103 Hematinics Phase 4,Phase 2,Phase 3,Phase 1
104 Incretins Phase 4,Phase 3,Phase 2
105 Cortisol succinate Phase 4
106 Hydrocortisone 17-butyrate 21-propionate Phase 4
107 Hydrocortisone acetate Phase 4
108 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
109 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1
110 Anticholesteremic Agents Phase 4,Phase 3,Phase 2
111 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
112 Antiparkinson Agents Phase 4,Phase 3,Phase 2
113 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
114 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
115 Central Nervous System Depressants Phase 4
116 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
117 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
118 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
119 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
120 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
121 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
122 Antineoplastic Agents, Phytogenic Phase 4,Phase 3
123 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
124 Platelet Aggregation Inhibitors Phase 4,Phase 3
125 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
126
Medroxyprogesterone Phase 4,Phase 3,Phase 1 520-85-4 10631
127 Antihypertensive Agents Phase 4
128 Antidotes Phase 4,Phase 2,Phase 3
129 Antiviral Agents Phase 4,Phase 2,Phase 3
130 Expectorants Phase 4,Phase 2,Phase 3
131 N-monoacetylcystine Phase 4,Phase 2,Phase 3
132 Respiratory System Agents Phase 4,Phase 2,Phase 3
133 Nicotinic Acids Phase 4
134 Vasodilator Agents Phase 4
135 Glucagon-Like Peptide 1 Phase 4,Phase 3
136 Mitogens Phase 4,Early Phase 1
137 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
138 Antidepressive Agents, Second-Generation Phase 4
139 Autonomic Agents Phase 4,Phase 3
140 Cholinergic Agents Phase 4
141 Cholinergic Antagonists Phase 4
142 Epinephryl borate Phase 4
143 Muscarinic Antagonists Phase 4
144 Neurotransmitter Uptake Inhibitors Phase 4
145 Parasympatholytics Phase 4
146
Serotonin Phase 4 50-67-9 5202
147 Serotonin Agents Phase 4
148 Serotonin Uptake Inhibitors Phase 4
149 Phosphodiesterase 4 Inhibitors Phase 4
150 Phosphodiesterase Inhibitors Phase 4
151 Follicle Stimulating Hormone Phase 4,Phase 3,Early Phase 1
152 Progestins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
153 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
154 HIV Protease Inhibitors Phase 4,Phase 3,Early Phase 1
155
protease inhibitors Phase 4,Phase 3,Early Phase 1
156 Sitagliptin Phosphate Phase 4
157 Phytoestrogens Phase 4
158 Vitamin B 12 Phase 4
159 Dermatologic Agents Phase 4
160 Cardiac Glycosides Phase 4
161 Glycoside Hydrolase Inhibitors Phase 4
162 Antiemetics Phase 4,Phase 3
163 glucocorticoids Phase 4,Phase 3
164 Thioctic Acid Phase 4,Phase 1
165 Dacuronium Phase 4
166 Tin Fluorides Phase 4
167 glucagon Phase 4,Phase 3
168 Methylprednisolone acetate Phase 4
169 Methylprednisolone Hemisuccinate Phase 4
170 Neuroprotective Agents Phase 4,Phase 3
171 Prednisolone acetate Phase 4
172 Prednisolone hemisuccinate Phase 4
173 Prednisolone phosphate Phase 4
174 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
175
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 77-92-9 311
176 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
177
Inositol Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Early Phase 1 87-89-8
178 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
179 carnitine Nutraceutical Phase 4
180 Calciferol Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
181 Vitamin D2 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
182 cysteine Nutraceutical Phase 4,Phase 2,Phase 3
183 Olive Nutraceutical Phase 4
184 Vitamin B3 Nutraceutical Phase 4
185
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
186
Methylcobalamin Experimental, Nutraceutical Phase 4 13422-55-4
187 Vitamin B12 Nutraceutical Phase 4
188 Alpha-lipoic Acid Nutraceutical Phase 4,Phase 1
189
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
190
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
191
Cetrorelix Approved, Investigational Phase 3,Phase 2 120287-85-6 16129715 25074887
192
Chromium Approved Phase 3 7440-47-3 27668
193
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
194
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
195
Saxagliptin Approved Phase 3 361442-04-8 11243969
196
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
197
Empagliflozin Approved Phase 2, Phase 3 864070-44-0
198
Phentermine Approved, Illicit Phase 3 122-09-8 4771
199
Topiramate Approved Phase 3 97240-79-4 5284627
200
Bisacodyl Approved Phase 2, Phase 3 603-50-9
201 Cinnamon Approved, Nutraceutical Phase 3,Phase 1
202 tannic acid Approved, Nutraceutical Phase 3,Phase 2
203
Lactitol Investigational Phase 3 585-86-4 3871
204 Dopamine Agents Phase 3,Phase 2
205 Dopamine agonists Phase 3,Phase 2
206 Prolactin Release-Inhibiting Factors Phase 3
207 Raloxifene Hydrochloride Phase 3
208 Calcifediol Phase 3 19356-17-3
209 Hydroxycholecalciferols Phase 3,Phase 2
210 BB 1101 Phase 3
211 Dexamethasone acetate Phase 3 1177-87-3
212 Anti-Bacterial Agents Phase 3
213 Antibiotics, Antitubercular Phase 3
214 Antimalarials Phase 3
215 Antiparasitic Agents Phase 3
216 Antiprotozoal Agents Phase 3
217 Matrix Metalloproteinase Inhibitors Phase 3
218 Anesthetics Phase 2, Phase 3
219
s 1 (combination) Phase 3
220 Gonadotropins, Pituitary Phase 3
221 Adrenergic Agents Phase 3
222 Cathartics Phase 2, Phase 3
223 Fenugreek seed meal Phase 2, Phase 3
224 Laxatives Phase 2, Phase 3
225 Anticonvulsants Phase 3
226 Central Nervous System Stimulants Phase 3
227 Calcium polycarbophil Phase 2, Phase 3
228 Fenugreek Nutraceutical Phase 2, Phase 3
229 Psyllium Nutraceutical Phase 2, Phase 3
230
Norethindrone Approved Phase 2 68-22-4 6230